Every other psychedelic shows you more.This one shows you less.

Psilocybin, LSD, ayahuasca — they alter perception. They produce imagery. They surface material. They can give you a new way to tell your story.

5-MeO does none of that. Time, space, and the sense of being a self located somewhere, looking out — these are not altered. They are briefly suspended. Researchers who study it call the resulting state deconstructed consciousness.

Every other tool works on the identity. It gives you distance from it, insight into it, a better version of it. 5-MeO does something categorically different: it briefly removes the assumption the identity is standing on — that there is a you in here and a world out there.

That assumption is where the whole structure begins. It is also the one thing no amount of work has ever reached.

Synthetic. Pharmaceutical-grade, lab-purity-tested, structurally identical to the molecule described above, and the form used in clinical trials.

5-MeO-DMT was first synthesised in a laboratory in 1936. It was identified in the secretion of the Sonoran Desert toad in 1965, and the practice of smoking that secretion spread from a pamphlet published in 1984. Synthetic is not a modern substitute for an older tradition. It predates that tradition by nearly fifty years.

You may also have heard that smoking the secretion is an ancestral practice of the Comcáac people of Sonora. Researchers who have worked in the region document that account as an invention of the last fifteen years, introduced to that community from outside, and carrying consequences for it that are still being written about.

The rest of the objection is analytical. Toad secretion contains 5-MeO alongside bufotenin and other alkaloids, in proportions that vary from animal to animal and that nobody has measured for the dose in front of you. A physician cannot clear a dose that has not been quantified, and a staged sequence cannot be calibrated against an unknown. Everything else on this site depends on knowing what is in the vial.

The species and the communities around it are under pressure from exactly this practice.¹ That is a real reason and it is not the first one.

In October 2025 the U.S. Food and Drug Administration granted Breakthrough Therapy designation to BPL-003 — an intranasal formulation of mebufotenin (5-MeO-DMT) developed by Beckley Psytech and atai Life Sciences, since merged as AtaiBeckley — for treatment-resistant depression. Following a successful End-of-Phase 2 meeting with the FDA, the company aligned on a two-study Phase 3 program.⁴The Usona Institute has completed a Phase 1 study of 5-MeO-DMT. GH Research is in Phase 2 with a 5-MeO compound for the same indication.⁵

In September 2026 Eli Lilly completed its acquisition of AtaiBeckley for approximately $2.8 billion, with up to $1 billion more tied to development and regulatory milestones. Initial Phase 3 results are expected in early 2029.⁶

None of that is ours. It belongs to a pharmaceutical company, a specific formulation, and a specific clinical indication — a nasal spray, given in a clinic, for treatment-resistant depression. It makes no claim about what we do, and we are not going to pretend otherwise.

What it tells you is narrower, and it is the only thing we would ask you to take from it. The regulator no longer treats this molecule as fringe.

5-MeO carries real contraindications. It interacts dangerously with MAOIs and with some psychiatric medications. It raises heart rate and blood pressure. A minority of people experience reactivations in the days that follow.

This is why eligibility is determined by a licensed physician, and not by us. It is why nobody reaches the day without clearing that first. And it is why anyone who tells you this is safe for everyone is selling you something.

The full harm-reduction protocol